REGEMAT 3D
Develops customizable 3D bioprinters and bioreactors for tissue engineering and regenerative medicine, enabling creation of functional human tissues for research and clinical applications.
- CEO / Founder
- José Manuel Baena
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $1.1M
- Latest Round
- Crowdfunding
- Key Investors
- European Commission; La Caixa Foundation; Spanish Ministry of Industry; University of Cadiz
Technology & Products
Key Products
BIO V1 3D bioprinter; REG4LIFE 3D bioprinter; BMAP Knee bioreactor; R3D Studio bioprinting software; GelMA-Graphene Kit bioink; Custom biomaterials and bioinks
Technological Advantage
Proprietary BMAP Knee bioreactor (patented in 2024) replicates human knee joint conditions for cartilage regeneration, protected by patents; modular bioprinter design allows customization for specific research needs, creating switching costs; first-mover in clinical-focused bioprinting solutions in Europe.
Differentiation
Value Proposition
Reduces tissue engineering development time by providing integrated bioprinting-bioreactor platforms that mimic human physiological conditions, accelerating research from months to weeks while enabling personalized regenerative therapies.
How They Differentiate
Offers integrated bioprinting-bioreactor systems while competitors focus primarily on bioprinters alone; modular customization allows specific configurations vs. competitors' standardized systems; patented BMAP Knee bioreactor provides unique functional tissue maturation capability not matched by general bioreactors.
Market & Competition
Target Customers
Research institutions, biotech companies, hospitals, academic labs, and industry professionals in regenerative medicine
Industry Verticals
Biotechnology; Medical Devices; Pharmaceuticals; Academic Research; Healthcare
Competitors
CELLINK; Organovo; Aspect Biosystems
Growth & Milestones
Growth Metrics
Expanded to over 35 countries with 60+ active projects worldwide; launched new products including GelMA-Graphene Kit and R3D Studio software in 2025.
Major Milestones
Founded in 2015; Launched BMAP Knee bioreactor (patented 2024); Expanded to 35+ countries by 2025; Partnership with Humabiologics for European distribution (2022); Launched R3D Studio software (2025)
Notable Customers
University of Nizwa (Oman); University of Seville; Sultan Qaboos University; Mansoura University